Rosuvastatin: An Effective Lipid Lowering Drug against Hypercholesterolemia (original) (raw)
2006, The Internet Journal of Cardiovascular Research
Hypercholesterolemia (HC) is primarily implicated in the progression of coronary heart disease (CHD) and its treatment is essential. Statin such as rosuvastatin, the lipid-lowering agent, is well known for its ability to normalize patient's serum cholesterol level. The study was designed, to compare the lipid-modifying efficacy of rosuvastatin across HC. The efficacy of rosuvastatin (10mg) was found in 162 patients who met the inclusion criteria [fasting Total cholesterol (TC) concentration ≥ 200mg/dl, low density lipoprotein-Cholesterol (LDL-C) ≥ 130mg/dl and triglyceride (TG) ≤ 300 mg/dl]. Selected patients were subdivided into two groups (group 1-TC ≤ 240 mg/dl and group 2-TC > 240 mg/dl). The efficacy was determined by measuring changes from baseline in lipid parameters including LDL-C, TC, TG, high density lipoprotein-Cholesterol (HDL-C) and non-high density lipoprotein-Cholesterol (NHDL-C). TC, LDL-C, and NHDL-C significantly (p<0.001) reduced over their baselines. Mean changes at 8 weeks were-24 to-28.3% for TC,-19.5 to-20.1% for TG,-33.3 to-38.7% for LDL-C,-31.3 to-35.6% for NHDL-C, 6.5 to 6.9% for HDL-C,-28.9 to-33.2% for TC/HDL-C,-37.6 to-42.9% for LDL-C/HDL-C and-35.8 to-40% for NHDL-C/HDL-C. Rosuvastatin produces good reduction in TC and beneficial changes in other lipid fractions in hypercholesterolemic patients and is well tolerated.